The Board of Directors (the ?Board?) of Femasys Inc. appointed Joshua Silverman as director of the Company effective November 21, 2023. There are no family relationships between Mr. Silverman and any Company director or executive officer, and no arrangements or understandings between Mr. Silverman and any other person pursuant to which he was selected as a director, other than the Securities Purchase Agreement. Mr. Silverman was appointed to the Board pursuant to the board nomination right granted to PharmaCyte Biotech Inc. (?PharmaCyte?) under the Securities Purchase Agreement, dated November 21, 2023 (the ?Securities Purchase Agreement?), by and among the Company, PharmaCyte and the other purchasers party thereto, which agreement is described in and filed as an exhibit to Current Report on Form 8-K filed with the SEC on November 15, 2023.

Joshua Silverman serves as the interim Chief Executive Officer, President and Director of PharmaCyte Biotech. He is the Co-Founder and Managing Member of Parkfield Funding LLC and is a former Principal and Managing Partner of Iroquois Capital Management, LLC. Previously, he served as Co-Chief Investment Officer of Iroquois from 2003 until 2016 and Co-Chief Investment Officer of Vertical Ventures, LLC from 2000 to 2003.

Mr. Silverman served as Assistant Press Secretary to The President of The United States. Mr. Silverman also serves on the boards of directors of Ayro Inc., MYMD Pharmaceuticals Inc., Petros Pharmaceuticals Inc. and Synaptogenix Inc. Mr. Silverman received his B.A. from Lehigh University.